Advertisement
Advertisement
U.S. markets open in 4 hours 30 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Theralase Technologies Inc. (TLTFF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.1698-0.0059 (-3.36%)
At close: 09:43AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1757
Open0.1530
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1530 - 0.1698
52 Week Range0.1500 - 0.3200
Volume1,100
Avg. Volume63,006
Market Cap37.89M
Beta (5Y Monthly)1.78
PE Ratio (TTM)N/A
EPS (TTM)-0.0200
Earnings DateNov 27, 2023 - Dec 01, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for TLTFF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • THERALASE TECHNOLOGIES INC
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, global EV adoption rate to rise; patience will be rewarded for U.S. REIT investors; key takeaways from renewable energy conference; and Fortrea Holdings, Apple, and Bristol-Myers Squibb.
    Rating
    Fair Value
    Economic Moat
    10 days agoMorningstar
View more
  • ACCESSWIRE

    Theralase(R) Grants Stock Options

    Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDCs"), their associated drug formulations and the light systems that activate them, intended to safely and effectively destroy various cancers, announces the grant of stock options.

  • ACCESSWIRE

    Theralase(R) Closes Private Placement Equity Financing

    Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), is a clinical stage pharmaceutical company focused on the research, development and commercialization of light activated Photo Dynamic Compounds ("PDCs"), their associated drug formulations and the light systems that activate them, to destroy various cancers, bacteria and viruses, safely and effectively, is pleased to announce that it has closed a non-brokered

  • ACCESSWIRE

    Theralase Release’s 2Q2023 Interim Financial Statements

    / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDCs"), their associated drug formulations and the light systems that activate them, intended to safely and effectively destroy various cancers has released the Company's 2Q2023 unaudited condensed interim consolidated Financial

Advertisement
Advertisement